艾昆纬

IQVIA's 15-minute chart triggers MACD Death Cross, KDJ Death Cross warning.

IQVIA: JP Morgan Downgrades to Overweight, PT Lowered to $225.

Citigroup

Citigroup lowers IQVIA PT to $200, maintains Neutral rating.

UBS Maintains Buy Rating on IQVIA, Lowers PT to $240 from $280.

IQVIA PT Lowered to $255, Jefferies Maintains Buy Rating

Catalyst<ul> <li>Most analysts rate IQV Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.</li> <li>At least one major firm maintains a Neutral rating, citing valuation concerns.</li> <li>Fund flow trends show large and extra-large order inflows are negative, indicating potential selling pressure.</li></ul>

Key Factors

IQVIA reported Q4 2025 earnings with $4.36 billion in revenue and $3.02 in EPS, both exceeding expectations, though shares fell due to weak long-term profit forecasts. IQVIA’s Q4 revenue reached $4.36 billion and adjusted EPS hit $3.42, both topping analyst estimates, with $2.1 billion in free cash flow generated for the year. JP Morgan downgraded IQVIA to Overweight with a price target of $225, while UBS and Jefferies also lowered their price targets but maintained Buy ratings.

IQV News